NL-OMON51765尚未招募不适用
Predictive model for the sensitising capacity of novel nutritional proteins. - PREFER study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Signed informed consent
- •18 years of age or older, mentally competent
- •Patients suspected of a food allergy to peanut, or cow's milk, or hen's egg
- •Complaints after consuming peanut, or cow's milk, or hen's egg
- •Positive Skin Prick test with peanut, or cow's milk, or hen's egg
排除标准
- •Patient eats peanut, or cow's milk, or hen's egg, without complaints
- •Negative skin prick test with peanut, or cow's milk, or hen's egg
- •Negative DBPCFC with peanut, or cow's milk, or hen's egg
- •Antihistamines used in the last 72 hours before the skin prick test and/or
- •Unable to stop beta-blockers
- •Use of more than 10 mg prednisone (relative contraindication)
研究者
相似试验
已完成
不适用
Human Repeat Insult Patch TestingCTRI/2019/09/021426The Himalaya Drug Company345
已完成
不适用
A prospective study on prediction of sensitivity to trastuzumab using gene expression of peripheral blood mononuclear cellsbresat cancerJPRN-UMIN000002660Chikako Shimizu, Kenji Tamura60
已完成
不适用
Exploration of Predictive factors for response to Enzaltamide in bone metastasis of Prostate cancerBone metastasis of prostate cancerJPRN-UMIN000018634Department of Urology, Juntendo University Graduate School of Medicine100
已完成
不适用
Characterization of the Sensitization Spectrum towards frequent and rare inhalation allergens in patients with severe asthma with special emphasis on regional differencesJ45.0J45.1J45.8Predominantly allergic asthmaNonallergic asthmaMixed asthmaDRKS00011586niversitätsklinik für Pneumologie1,016
进行中（未招募）
1 期
Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen Markern auf die Wirksamkeit und Nebenwirkungsrate bei postmenopausalen, steroidhormonrezeptorpositiven Mammakarzinomspatientinnen, die mit Letrozol behandelt werden. - PreFaceEUCTR2008-004874-42-DEInstitut für Frauengesundheit GmbH3,500